EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Why FNA When You Can FNB? Tissue Acquisition for Solid Lesions in the FNB Era

I. Braimakis, N.L.H. Bekkali

Journal of Digestive Endoscopy · 01.03.2026 · 17 (S 01 S 01) · S1-S138

DOI: 10.1055/s-0046-1828876 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Digestive Endoscopy, erschienen am 01.03.2026. Verfasst von I. Braimakis und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Endoscopic ultrasound (EUS)-guided tissue acquisition (EUS-TA) has been incorporated in the diagnostic pathway of hepatopancreatobiliary (HPB) and gastrointestinal diseases over the past three decades. Initially, EUS-fine-needle aspiration (EUS-FNA) was introduced into clinical practice, rapidly becoming the standard technique for EUS-TA. This technique allowed for the endoscopic acquisition of samples for cytological diagnosis, while maintaining adequate safety profile and diagnostic accuracy. For nearly two decades, EUS-FNA represented one of the greatest advances in tissue acquisition, with diagnostic accuracies exceeding 85 to 90% for pancreatic malignancy when rapid onsite cytopathological evaluation (ROSE) was available, establishing FNA as the benchmark against which all subsequent tissue acquisition devices were compared. However, recent developments in oncology treatment have shifted tissue acquisition beyond establishing a simple cytological diagnosis. The preservation of tissue architecture, immunohistochemistry staining, and molecular profiling through next-generation sequencing was considered a requirement in this context. Furthermore, a number of gastrointestinal diseases, including lymphoma, gastrointestinal stromal tumors (GISTs), autoimmune pancreatitis (AIP), and neuroendocrine tumors, cannot be reliably diagnosed by cytology alone. This need for histological assessment of the acquired samples exposed the limitations of the EUS-FNA. To overcome these limitations, fine-needle biopsy (FNB) needles were developed in order to obtain biopsy cores with intact architecture. The first-generation 19-gauge Tru-Cut and reverse-bevel needles, demonstrated inconsistent performance and technical limitations. However, the introduction of third-generation end-cutting needles, including the Franseen and fork-tip designs, improved the outcomes, resulting in a significant change in EUS-TA. Over the past decade, an increasing number of randomized controlled trials (RCTs), systematic reviews, and international guidelines have compared the outcomes of EUS-FNA and EUS-FNB. Accumulating evidence demonstrates improved histological yield, reduced procedural time, need for fewer passes, and decreased dependence on ROSE with modern end-cutting FNB needles. Consequently, recent recommendations from the European Society of Gastrointestinal Endoscopy (ESGE), favor FNB as the preferred EUS-TA technique for most solid lesions, while reserving FNA for selected circumstances. This review examines the evolution of EUS-TA from aspiration to biopsy, discusses their role in different clinical scenarios, and evaluates whether FNB should now be considered the preferred technique for EUS-TA of solid HPB and gastrointestinal lesions. Why Histology Matters During the early years of implementation of EUS-FNA into clinical practice, establishing a cytological diagnosis of malignancy was often sufficient to guide clinical management. In cases with unresectable pancreatic cancer, cytological confirmation frequently represented the final diagnostic step before initiation of palliative chemotherapy. In this context, the adequate diagnostic accuracy, safety profile, and minimal invasive nature of EUS-FNA, lead to its establishment as a standard technique for EUS-TA. However, recent advances in oncology have made detailed histopathological assessment, immunophenotyping, and molecular characterization of tumor tissue, essential in forming an oncological management plan. More detailed histopathological evaluation requires preservation of tissue architecture in addition to conventional cytology. These advances made adequate core tissue acquisition an essential component of oncology decision-making, signaling a shift from mere confirmation of malignancy. This shift has uncovered the limitations of EUS-FNA. Although FNA specimens may contain abundant individual cells, the disruption of tissue architecture limits the ability to proceed with detailed histopathological assessment. This limitation is particularly apparent in gastrointestinal diseases in which tissue architecture is also fundamental to diagnosis. In this context, GISTs require immunohistochemical confirmation to distinguish them from leiomyomas, schwannomas, and other mesenchymal tumors. Similarly, lymphoma diagnosis frequently requires the assessment of nodal architecture, immunophenotyping, and, in some cases, flow cytometry. Although pancreatic ductal adenocarcinoma (PDAC) can frequently be diagnosed cytologically, several benign diseases closely resemble malignancy on cross-sectional imaging. AIP represents perhaps the clearest example. The International Consensus Diagnostic Criteria rely heavily on histological features to diagnose AIP, findings that are generally absent or impossible to assess in cytology specimens obtained by EUS-FNA. Consequently, the diagnostic utility of FNA in suspected AIP is limited. Therefore, preserved histological architecture is also important in pancreatic disease. Similar limitations of EUS-FNA have also been recognized in neuroendocrine tumor cases, where assessment of Ki-67 immunostaining is essential for tumor grading. Although Ki-67 assessment is technically feasible on cytological material, larger histological specimens generally provide more representative tumor sampling and reduce the risk of grading error due to tumor heterogeneity. Additionally, advances in precision oncology are highly dependent on molecular profiling using next-generation sequencing. Identification of actionable genomic alterations may influence management decisions, therefore obtaining sufficient samples have become an important objective of EUS-TA. Several studies have demonstrated that samples obtained using FNB needles are more likely to result in adequate material for comprehensive molecular analysis than conventional EUS-FNA. Consequently, the ideal biopsy specimen is considered the one that provides sufficient tissue to establish a definitive diagnosis, with the minimum number of needle passes, while preserving tissue architecture. To achieve that, FNB needles were developed. Evolution of FNB The inherent limitations of EUS-FNA needles prompted the development of dedicated FNB needles. These were initially introduced in the early 2000s with the 19G Tru-Cut biopsy needle. Even though this allowed the acquisition of a cylindrical tissue core with preserved architecture, the large caliber and rigid construction made sampling technically difficult, particularly for pancreatic lesions. Subsequently, the reverse-bevel ProCore needle was introduced. This incorporated improvements in sampling technique, with smaller gauges also available. Even though the reverse-bevel needle resulted in larger tissue fragments when compared to FNA, it did not result in meaningful improvement in diagnostic accuracy. Several randomized trials demonstrated comparable diagnostic performance between reverse-bevel FNB and conventional FNA. Furthermore, meta-analyses performed during this period concluded that reverse-bevel FNB alone could not establish clear superiority over conventional FNA. This was addressed with the development of the third-generation end-cutting FNB needles, including the Franseen needle and the fork-tip needle. Although their engineering differs, both designs were able to optimize histological preservation. The introduction of end-cutting needles resulted in improvements in specimen adequacy, and therefore in diagnostic accuracy and procedural efficiency, with adequate safety profile. Beyond improved tissue acquisition, end-cutting FNB needles have altered the workflow of EUS-TA. The core specimens acquired have facilitated macroscopic/visual onsite evaluation (MOSE/VOSE), whereby the endoscopist can visually assess specimen adequacy based on the presence of an intact whitish tissue core. This approach reduces dependence on ROSE, an increasingly scarce resource outside high-volume tertiary centers. The current ESGE recommendations therefore support the use of MOSE with end-cutting FNB needles, while reserving ROSE primarily for centers where conventional FNA remains standard practice. Does FNB Improve Clinical Outcomes? Over the past decade, numerous RCTs and meta-analyses have compared FNB with FNA outcomes. Diagnostic accuracy remains the most frequently reported endpoint in comparative studies of EUS-TA. A comprehensive meta-analysis published in 2021, incorporating 18 RCTs and 2,718 patients, demonstrated a significantly higher overall diagnostic accuracy with FNB compared with FNA (87% vs. 80%). In addition, FNB resulted in substantially higher rates of histological core acquisition (80% vs. 62%). Of note, these improvements were achieved with fewer needle passes. These findings have subsequently been supported by additional systematic reviews. A 2022 meta-analysis similarly revealed better diagnostic accuracy with FNB compared with FNA, along with a reduction in the number of needle passes required. The reduction in the number of the required needle passes does not only mean reduction in procedural time but also limits patient discomfort, decreases the cumulative trauma to the target lesion, and reduces the sedation dose. All these factors could result in better safety profile while maintaining the diagnostic accuracy of the procedure. ROSE and MOSE For many years, ROSE was considered a cornerstone in EUS-TA. The immediate assessment of the acquired tissue samples onsite by a cytopathologist reduced the risk of inadequate sampling and repeat procedures. However, this required dedicated cytopathology personnel to be present during the procedure, significantly increasing health care costs and complicating the logistics of organizing and providing a consistent EUS service. Development of FNB needles has challenged the necessity of ROSE. Accordingly, a multicenter RCT published in 2022 demonstrated the noninferiority of FNB without ROSE when compared to FNA with ROSE. Additional studies have reached similar conclusions, indicating that FNB, especially when MOSE/VOSE is utilized, provides a pragmatic alternative that maintains diagnostic performance while simplifying procedural logistics. Clinical Applications Recent evidence increasingly favors the use of FNB in the diagnosis of pancreatic masses. A 2024 meta-analysis including 12 comparative studies reported significantly higher diagnostic accuracy with FNB, and this with fewer needle passes. One notable systematic review by Li and colleagues found no significant difference in overall diagnostic yield between FNA and FNB in pancreatic masses. Importantly, however, FNB still required fewer needle passes and provided superior histological specimens. These findings lead to a shift in the societies’ recommendations, with international guidelines increasingly favoring FNB as the preferred technique for pancreatic tissue acquisition despite relatively small differences in overall diagnostic accuracy. For subepithelial lesions, EUS effectively helps with diagnosis and management. By determining the layer of origin and the echogenicity of a lesion, the EUS is able to help with the diagnostic process. However, in selected cases, like GISTs, histological confirmation is essential in the differential diagnosis from leiomyomas, schwannomas, or other mesenchymal neoplasms. It is well known that GISTs require expression of KIT (CD117), DOG1, and frequently CD34 for definitive diagnosis, while assessment of spindle-cell morphology and mitotic activity contributes to risk stratification. This detailed assessment is better served with the adequate tissue samples acquired with FNB. The superiority of FNB in this setting has been consistently demonstrated. A meta-analysis by Facciorusso and colleagues, including 10 comparative studies, reported a diagnostic accuracy approaching 95% for FNB compared with approximately 81% for conventional FNA. With regards to lymphoma, while FNA may still identify an atypical lymphoid population, accurate classification according to the World Health Organization system frequently requires preservation of nodal architecture along with immunophenotyping. To achieve that, the larger tissue samples are of paramount importance, and this is where FNB is found to be beneficial. In this context, although comparative RCTs remain limited, a number of observational studies do report higher diagnostic adequacy for lymphoma with FNB than with FNA. Additionally, the utilization of EUS-TA in the diagnostic workup and management of NETs is well established. The acquisition of sufficient samples for grading, immunohistochemistry, and assessment of proliferative activity using the Ki-67 index is considered highly important, as this affects tumor grading and subsequently informs prognosis and therapeutic decision-making. Although Ki-67 can be assessed on cytology, recent data have demonstrated improved concordance between biopsy specimens and final surgical pathology when histological cores are available. AIP represents perhaps the clearest example of why histology has become increasingly important in EUS-TA. Differentiating AIP from PDAC remains a great diagnostic challenge, given that both conditions may present with a focal pancreatic mass and obstructive jaundice. The diagnosis of AIP relies heavily on characteristic histopathological findings. The International Consensus Diagnostic Criteria recognize lymphoplasmacytic infiltrates, storiform fibrosis, and obliterative phlebitis as hallmark features of type 1 AIP, together with abundant IgG4-positive plasma cells. These architectural features cannot be reliably evaluated using cytology alone. In this context, the development of third-generation end-cutting FNB needles has improved tissue acquisition in suspected AIP. When compared with FNA, the Franseen and fork-tip needles obtain larger histological cores with better preservation of tissue architecture, increasing the likelihood of successfully establishing the diagnosis. Consequently, the recent ESGE guidance recommends end-cutting FNB needles as the preferred technique in suspected AIP. Safety Profile Multiple RCTs and subsequent meta-analyses have consistently demonstrated comparable safety profiles for FNA and FNB. Overall adverse event rates remain low, generally below 2 to 3%, irrespective of needle design. The most frequently reported complications include mild pancreatitis, bleeding, and transient abdominal pain, with clinically significant hemorrhage or perforation occurring only rarely. Overall, evidence indicates that the improved histological performance of FNB has been achieved without compromising patients’ safety, supporting its routine use.

Conclusion

The utilization of EUS-FNA in clinical practice was one of the most important advances in diagnostic EUS. However, the requirements for tissue acquisition have evolved considerably. Modern pathology increasingly demands preserved tissue architecture, immunohistochemistry, and molecular analysis. These changes in expectations have exposed the intrinsic limitations of EUS-FNA sampling and driven the development of dedicated FNB needles. The evidence accumulated over the past decade demonstrates that third-generation end-cutting FNB needles achieve superior histological core acquisition, require fewer needle passes, and achieve at least equivalent, and frequently superior, diagnostic accuracy compared with FNA needles. Importantly, these improvements have been achieved without increasing procedure-related adverse events. Moreover, FNB needles perform adequately without the need for ROSE, reducing health care costs. Publication History Article published online: 27 August 2026 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical and Scientific Publishers Private Limited A-13A, Graphix Tower 1, 6th floor, Sector 62, Noida 201309, Uttar Pradesh, India

Zitieren

APA

Braimakis, I., & Bekkali, N. (2026). Why FNA When You Can FNB? Tissue Acquisition for Solid Lesions in the FNB Era. Journal of Digestive Endoscopy, 17(S 01 S 01), S1-S138. https://doi.org/10.1055/s-0046-1828876

Vancouver

Braimakis I, Bekkali N. Why FNA When You Can FNB? Tissue Acquisition for Solid Lesions in the FNB Era. Journal of Digestive Endoscopy. 2026;17(S 01 S 01):S1-S138. doi:10.1055/s-0046-1828876

BibTeX
@article{Braimakis2026,
  author = {Braimakis, I. and Bekkali, N.L.H.},
  title = {Why FNA When You Can FNB? Tissue Acquisition for Solid Lesions in the FNB Era},
  journal = {Journal of Digestive Endoscopy},
  year = {2026},
  volume = {17},
  number = {S 01 S 01},
  pages = {S1--S138},
  doi = {10.1055/s-0046-1828876}
}
Kostenlos starten →